Healthpeak Properties (DOC) has reaffirmed a monthly cash dividend of $0.10167 per share for the third quarter of 2026, giving income focused investors clear record and payment dates to plan around.
See our latest analysis for Healthpeak Properties.
The dividend affirmation follows a strong run in Healthpeak Properties' stock, with a 30 day share price return of 11.15% and a 90 day share price return of 28.56%. The 1 year total shareholder return of 30.26% contrasts with a 5 year total shareholder return that remains in decline by 18.23%, suggesting recent momentum has picked up from a weaker longer term base.
If this recent move has you thinking about what else is working in income and infrastructure linked themes, it could be worth scanning 35 power grid technology and infrastructure stocks.
After Healthpeak Properties' sharp share price move and a market price of $22.33 that now sits close to the average analyst target of $22.18, yet at a 41% discount to one intrinsic estimate, the question is where fair value really sits.
Compared with the Simply Wall St fair value estimate of $21.44, Healthpeak Properties at $22.33 sits slightly above what the most followed narrative considers reasonable, even after factoring in the recent rerating.
The analysts have a consensus price target of $21.44 for Healthpeak Properties based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $29.0, and the most bearish reporting a price target of just $17.0.
Want to see what is sitting under that tight spread between current price and fair value? The narrative leans heavily on modest revenue growth, thinner profit margins and a future earnings multiple that assumes investors will keep paying up for this health care REIT profile.
Result: Fair Value of $21.44 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Healthpeak Properties narrative could be knocked off course if capital market conditions stay tight or if key biotech and healthcare tenants struggle to meet lease commitments.
Find out about the key risks to this Healthpeak Properties narrative.
While the analyst consensus suggests Healthpeak Properties is about 4.1% overvalued at $22.33 versus a $21.44 target, the Simply Wall St DCF model points the other way, with a fair value estimate of $38.08. That implies the stock trades at a 41.4% discount, which is a very different story.
For investors, that gap raises a practical question: are analysts being too cautious about slower forecast earnings, or is the DCF model too optimistic about future cash flows and required returns?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Healthpeak Properties for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Given the mixed signals around Healthpeak Properties and its dividend story, this is a moment to review the underlying data, weigh the 1 key reward against the 4 important warning signs that investors are focused on, and decide what matters most for your style of investing. Start with 1 key reward and 4 important warning signs
If Healthpeak Properties has sharpened your focus, do not stop here. Broader opportunities across income, quality and growth themes could fit even better with your goals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com